Table 3.

Gene-based association of SPATA13-AS1 with short-acting beta-agonist use among individuals with asthma.^*

Gene	Chromosome	Set with existing genome wide genotype data†	Sets without existing genome wide genotype data‡		All groups with asthma combined (n= 3,182)
		African American individuals with asthma (n=658)	European American individuals with asthma (n=556)	African American individuals with asthma (n=1,968)
SPATA13-AS1	13	0.047	0.384	0.025	0.014

^*Shown are the p-values for gene-based associations generated using the GATES procedure.⁽¹⁶⁾ This procedure combines the single nucleotide polymorphism (SNP) associations around and within a given gene. The outcome variable, short-acting beta-agonist (SABA) use, was based on the number of SABA fills in pharmacy claims data. These data were only available for health plan members with pharmaceutical coverage, hence the smaller sample size.

^†Adjusted for age, sex, body mass index (BMI), percent of predicted forced expiratory volume at one second (FEV₁), smoking status, and principal components for population substructure. The association also accounted for cryptic relatedness between subjects.

^‡Adjusted for age, sex, BMI, percent of predicted FEV₁, and smoking status.